Justin Stebbing

Overview

Justin Stebbing is a British clinician-scientist specializing in oncology and cancer research. He holds a medical degree from Trinity College, Oxford, and completed his residency at The Johns Hopkins Hospital in the United States. He has served as a Professor of Oncology at Imperial College London and has published over 700 peer-reviewed papers. During the COVID-19 pandemic, his work led to the FDA approval of baricitinib as a treatment for COVID-19. In addition to his medical career, Dr. Stebbing has been involved in healthcare investing, working with firms such as Atticus Capital, Lansdowne Partners, and Vitruvian Partners. He previously chaired the board of BB Healthcare Trust, a UK-based investment trust focused on healthcare companies. He currently serves as a director of Etira Therapeutics and Graviton Biosciences BV. Dr. Stebbing is also the Editor-in-Chief of the journal Oncogene and a member of the American Society for Clinical Investigation. He holds the distinction of being the first oncology professor funded by the National Institute for Health Research (NIHR) in the UK. His investment activities have primarily focused on healthcare companies, with investments ranging from $1 million to $50 million. His geographical focus includes the United Kingdom, United States, Switzerland, Germany, France, Italy, Spain, Netherlands, Belgium, Sweden, Denmark, Norway, Finland, Ireland, Canada, Australia, New Zealand, Japan, South Korea, and China. The industries he invests in encompass healthcare, biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, medical research, clinical trials, oncology, immunology, neurology, cardiology, endocrinology, and pulmonology.

Investment Focus

• Healthcare focus
• Growth, Late Stage, or Pre-IPO companies
• Investments ranging from $1 million to $50 million
• Geographical focus on United Kingdom, United States, Switzerland, Germany, France, Italy, Spain, Netherlands, Belgium, Sweden, Denmark, Norway, Finland, Ireland, Canada, Australia, New Zealand, Japan, South Korea, and China
• Industries including healthcare, biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, healthcare IT, medical research, clinical trials, oncology, immunology, neurology, cardiology, endocrinology, and pulmonology

Portfolio Companies